Liu Rongqiang, Wang Ling, Ye Jing, Li Xinyi, Ma Wangbin, Xu Ximing, Yu Jia, Wang Weixing
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Front Immunol. 2025 Apr 8;16:1560944. doi: 10.3389/fimmu.2025.1560944. eCollection 2025.
The Glasgow Prognostic Score (GPS) is a well-established prognostic indicator that effectively reflects the inflammatory, nutritional, and immune status of cancer patients. GPS has been shown to be associated with survival outcomes in many different cancers. However, its prognostic significance in biliary tract cancer (BTC) remains unclear. This meta-analysis aims to explore the prognostic value of GPS in BTC patients.
A systematic search was conducted in PubMed, Embase, and Web of Science to identify relevant studies. Survival data including overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) were the main observation indicators. Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted and pooled for meta-analysis.
A total of 16 articles incorporating 1919 patients were included in the study. High GPS was associated with poor OS (HR:2.00, 95% CI:1.62-2.48) and DFS/RFS (HR:2.50, 95% CI:1.71-3.65). Subgroup analysis further confirmed the prognosis value of GPS in BTC patients.
GPS could serves as a valuable prognostic marker in BTC patients and may aid in risk stratification and treatment decision-making.
格拉斯哥预后评分(GPS)是一种公认的预后指标,能有效反映癌症患者的炎症、营养和免疫状态。GPS已被证明与多种不同癌症的生存结果相关。然而,其在胆管癌(BTC)中的预后意义仍不明确。本荟萃分析旨在探讨GPS在BTC患者中的预后价值。
在PubMed、Embase和Web of Science中进行系统检索以识别相关研究。生存数据包括总生存期(OS)、无病生存期(DFS)和无复发生存期(RFS)是主要观察指标。提取并汇总具有95%置信区间(CIs)的风险比(HRs)进行荟萃分析。
本研究共纳入16篇文章,涉及1919例患者。高GPS与较差的OS(HR:2.00,95%CI:1.62 - 2.48)和DFS/RFS(HR:2.50,95%CI:1.71 - 3.65)相关。亚组分析进一步证实了GPS在BTC患者中的预后价值。
GPS可作为BTC患者有价值的预后标志物,并可能有助于风险分层和治疗决策。